Lytix Biopharma ASA
LYTIX.OLDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LTX-109 | Phase 2 | Gram-positive, Skin Infections | - | - |
LTX-109 1 % | Phase 2 | Non-bullous Impetigo | - | - |
Frequently asked questions
What is in Lytix Biopharma ASA's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Lytix Biopharma ASA's (LYTIX.OL) pipeline across Phase 2. Its lead program is LTX-109 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lytix Biopharma ASA's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Lytix Biopharma ASA (LYTIX.OL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LYTIX.OL biotech catalysts?→
Add LYTIX.OL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lytix Biopharma ASA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.